Silicon Laboratories Inc. — Form 10-Q Summary
Reporting period: The filing covers the quarter ended March 30, 2013 (first quarter of fiscal 2013), compared mainly with the quarter ended March 31, 2012. The request metadata says “2012 Q1,” but the filing itself reports 2013 Q1.
Business context
Silicon Laboratories designs analog-intensive, mixed-signal integrated circuits for communications, consumer, industrial and automotive applications. It operates a fabless model, relying on third parties—primarily in Asia—for wafer fabrication, assembly and testing. The Ember acquisition, completed in July 2012, contributed to the current-period revenue comparison. Samsung represented more than 10% of quarterly revenue; two distributors, Edom Technology and Avnet, also each represented more than 10%. 89% of revenue came from outside the United States.
Key financial results
| Metric | Q1 2013 | Q1 2012 | Change / context |
|---|---|---|---|
| Revenue | $145.4 million | $125.7 million | Up 15.7%; units rose 9.7% and average selling prices rose 5.4% |
| Gross profit / margin | $87.4 million / 60.1% | $75.1 million / 59.7% | Gross profit up 16.3%; margin up 0.4 percentage points |
| Operating expenses | $66.7 million | $58.3 million | R&D $37.6 million; SG&A $29.2 million |
| Operating income / margin | $20.6 million / 14.2% | $16.8 million / 13.3% | Improved year over year |
| Net income | $20.0 million | $14.3 million | Up 39.9%; diluted EPS $0.46 vs. $0.33 |
| Operating cash flow | $29.5 million | $26.1 million | Up $3.4 million |
| Investing cash flow | $(58.3) million | $(25.6) million | Higher investment purchases and lower proceeds from maturities/sales |
Financial position and liquidity
- At March 30, 2013, cash and cash equivalents were $79.3 million and short-term investments were $229.8 million. Management reported $309.1 million in cash, cash equivalents and short-term investments; approximately $172.6 million was held by U.S. entities.
- Total assets were $896.6 million and stockholders’ equity was $680.9 million. Current assets were $502.7 million versus current liabilities of $103.8 million.
- Debt totaled $97.5 million: $5.0 million current and $92.5 million long-term. The company had not drawn on its $130 million revolving facility and reported compliance with its credit-facility covenants.
- Cash and cash equivalents fell by $26.2 million during the quarter, to $79.3 million. Inventory rose to $56.9 million from $49.6 million; management attributed the increase to demand differing from forecasts and inventory builds for new-product ramps. Days of inventory increased to 88 from 76.
- Management said existing liquidity and credit availability were sufficient to meet capital requirements for at least the next 12 months. Fiscal 2013 capital expenditures were expected to be approximately $14–$18 million.
Material changes and unusual items
- Revenue growth reflected market-share gains and Ember-related sales, as well as higher unit volume and average selling prices.
- R&D expense increased 14.1%, including higher personnel costs, Ember-related personnel and intangible amortization, and a $0.5 million asset impairment. SG&A increased 14.8%, with higher personnel and litigation legal costs partly offset by a reduction in acquisition-related contingent consideration.
- The effective tax rate was 0.2%, versus 16.3% a year earlier. The main factor was the retroactive reinstatement of the federal R&D tax credit, producing a benefit related to fiscal 2012 in this quarter. This materially boosted reported net income and limits direct comparability.
- The company recognized a $2.75 million gain in earnings after revising its estimate that an Ember acquisition milestone would be achieved, eliminating the related contingent consideration liability.
- Interest expense increased to $0.8 million from $0.03 million, principally because of the term loan. A $100 million interest-rate swap fixed the loan’s LIBOR component at 0.764%; the stated combined loan rate was 2.514% at quarter-end.
- The board authorized a new share repurchase program of up to $50 million through January 2014. No shares were repurchased during the quarter.
Outlook, risks and contingencies
- For fiscal Q2 2013, management expected revenue of $140–$146 million and diluted EPS of $0.30–$0.36. It expected R&D and SG&A to increase modestly in absolute dollars in Q2.
- Management cautioned that quarterly results are subject to semiconductor cyclicality, seasonality, product mix and pricing pressure. Product sales depend on customer design wins and qualification cycles, and the company’s sales cycle can be lengthy.
- Key exposures include customer concentration, dependence on third-party manufacturing and assembly capacity, forecast-driven inventory risk, international operations, competition, and the ability to develop products that gain market acceptance. The filing also highlights geographic concentration of suppliers and customers in the Pacific Rim.
- All $12.5 million par value of auction-rate securities remained subject to failed auctions, with contractual maturities from 2033 to 2046. The company received underlying cash flows but could not predict when principal would become accessible. It reported no other-than-temporary impairment.
- Patent litigation with MaxLinear involved claims and counterclaims concerning patent validity and infringement; the company said it could not predict the outcome or financial impact. Other ordinary-course legal proceedings were not expected to have a material adverse effect.
- Gross unrecognized tax benefits were $4.3 million, of which $4.1 million would affect the effective tax rate if recognized. The IRS was examining the company’s 2009–2011 federal returns; management did not expect the examination to materially affect financial position or results.
Most important facts for investors to verify
- Whether the Q2 revenue and diluted EPS outlook was achieved, and how actual results compare with the stated ranges.
- How much of Q1 earnings growth was driven by recurring operating performance versus the retroactive R&D tax-credit benefit and the contingent-consideration gain.
- Whether inventory and days of inventory normalize, and whether forecast mismatches lead to write-downs.
- Revenue exposure to Samsung and major distributors, customer demand trends, and changes in pricing or product mix.
- Availability and valuation of failed-auction securities, compliance with debt covenants, and the status and potential impact of the MaxLinear litigation and tax examination.